The efficacy and tolerability of intermediate high dose interferon alpha 2B treatment as an adjuvant therapy of high risk malignant melanoma [Yüksek riskli malign melanomun adjuvan tedavisinde orta yüksek doz i·nterferon alfa-2B tedavisinin etkinligi ve tolerabilitesi]

Basit Öğe Kaydı
dc.contributor.authorKarabulut B.
dc.contributor.authorSezgin V.C.
dc.contributor.authorGöksel G.
dc.contributor.authorŞanli U.A.
dc.contributor.authorUslu R.
dc.contributor.authorGöker E.
dc.date.accessioned2019-10-27T00:10:55Z
dc.date.available2019-10-27T00:10:55Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractThere are still ongoing clinical trials and debates about adjuvant treatment of malignant melanoma. Between 1995 and 2004, fourty-nine patients with high risk operated non-metastatic malignant melanoma who had been treated with intermediate dose of interferon alpha were enrolled to the study. Twenty-three patients had regional lymph node metastasis at the time of diagnosis. Patients were treated with interferon alpha 2b (10 million units/day, five times a week for four weeks) as an induction therapy, followed by interferon alpha 2b (10 million units/day interferon three times a week for eleven months) as a maintanence therapy. The median follow-up time was 35 months (range 2-101 months). In this period, 7(14%) of patients had local recurrence, 12 (24%) of patients had regional lymph node metastasis and 20 (41%) of patients had distant metastasis. The 5-years overall survival, disease free survival and distant metastasis free survival rate of patients were 68%, 32% and 54% respectively. Therapy was well tolerated, no grade 4 toxicity related to therapy was observed. Comparing to natural history of malignant melanoma, these results are found to be encouraged.en_US
dc.identifier.endpage14en_US
dc.identifier.issn1301-8825
dc.identifier.issn1301-8825en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage6en_US
dc.identifier.urihttps://hdl.handle.net/11454/22071
dc.identifier.volume15en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofTHOD - Turk Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvant therapyen_US
dc.subjectInterferon alpha 2Ben_US
dc.subjectMalignant melanomaen_US
dc.titleThe efficacy and tolerability of intermediate high dose interferon alpha 2B treatment as an adjuvant therapy of high risk malignant melanoma [Yüksek riskli malign melanomun adjuvan tedavisinde orta yüksek doz i·nterferon alfa-2B tedavisinin etkinligi ve tolerabilitesi]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu